Lifesci Capital Has Pessimistic View of VRDN Q3 Earnings

Key Points

• Lifesci Capital has downgraded its estimate for Viridian Therapeutics' Q3 2025 earnings per share from ($0.90) to ($1.03).
• Despite the downgrade, HC Wainwright restated a "buy" rating with a target price of $34.00, while other analysts have varied price targets for the stock, indicating mixed sentiments.
• Viridian Therapeutics recently reported a Q2 EPS of ($1.00), meeting analysts' consensus, with revenue showing a 4.2% year-over-year increase to $0.08 million.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Stock analysts at Lifesci Capital reduced their Q3 2025 earnings estimates for Viridian Therapeutics in a research note issued on Wednesday, August 6th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per share of ($1.03) for the quarter, down from their previous estimate of ($0.90). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Lifesci Capital also issued estimates for Viridian Therapeutics' Q4 2025 earnings at ($1.06) EPS and FY2025 earnings at ($3.96) EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, meeting the consensus estimate of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The business had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.05 million. During the same quarter in the previous year, the business posted ($0.81) earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year.

VRDN has been the subject of a number of other research reports. HC Wainwright reissued a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Royal Bank Of Canada reduced their target price on shares of Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Wells Fargo & Company dropped their price target on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. JMP Securities dropped their price target on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Oppenheimer increased their target price on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $37.00.

Viridian Therapeutics Stock Up 6.4%

Viridian Therapeutics stock traded up $1.08 during mid-day trading on Monday, reaching $17.97. The stock had a trading volume of 923,890 shares, compared to its average volume of 897,902. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -4.69 and a beta of 0.42. The company has a 50-day moving average price of $16.00 and a two-hundred day moving average price of $15.16. Viridian Therapeutics has a one year low of $9.90 and a one year high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.01 and a quick ratio of 11.01.

Institutional Investors Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VRDN. Geode Capital Management LLC lifted its holdings in Viridian Therapeutics by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 1,658,980 shares of the company's stock valued at $31,809,000 after acquiring an additional 165,669 shares during the period. ExodusPoint Capital Management LP acquired a new position in Viridian Therapeutics in the 4th quarter valued at $493,000. Invesco Ltd. increased its stake in shares of Viridian Therapeutics by 59.5% in the 4th quarter. Invesco Ltd. now owns 33,099 shares of the company's stock worth $635,000 after acquiring an additional 12,350 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Viridian Therapeutics by 8.4% in the 4th quarter. Legal & General Group Plc now owns 60,202 shares of the company's stock worth $1,154,000 after acquiring an additional 4,650 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Viridian Therapeutics by 522.8% in the 4th quarter. Renaissance Technologies LLC now owns 371,200 shares of the company's stock worth $7,116,000 after acquiring an additional 311,600 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.